Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocurest Plus Neo
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Ocurest Plus Neo** is an approved sterile ophthalmic solution developed and marketed by Centaur Pharmaceuticals for the management of ocular allergy, non-infectious eye irritation, redness, and discomfort. It is a fixed-dose combination containing boric acid, glycerin, sodium borate, and zinc sulfate, along with cooling agents such as menthol and camphor. Boric acid and sodium borate serve as mild antiseptics and buffering agents to maintain physiological pH. Zinc sulfate acts as an astringent to reduce redness and congestion, while glycerin functions as a demulcent and lubricant to hydrate and protect the ocular surface. The formulation is administered topically as eye drops to provide rapid, soothing relief from environmental irritants like dust, smoke, and wind.
- Brand names
- BioculaOcurest Plus NeoOptihist Soothe
- Other names
- boric acid + glycerin + sodium borate + zinc sulfateboric acid + glycerin + sodium borate + zinc sulphateboric acid + glycerol + sodium borate + zinc sulfateboric acid + glycerol + sodium borate + zinc sulphate
02
Targets
TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on Ocurest Plus Neo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocurest Plus Neo.